The Scientist asks Brigham and Women’s Hospital infectious disease specialist Lindsey Baden about testing for prior infections.

IgA antibodies appear to bind to specific species of commensal gut bacteria in mice, according to a study.

How scientists aim to induce an immune response against addictive drugs

Researchers are turning to the immune system for help in treating addiction and preventing overdose.

President Biden’s planned rollout of additional COVID-19 vaccine doses is set to begin next week, but questions remain about who should get them.

Some of the blood specimens collected in the United States for the NIH’s All of Us research program starting on January 2, 2020, have antibodies against SARS-CoV-2.

Engineered viruses that don’t replicate provide a tractable model for scientists to safely study SARS-CoV-2, including research into vaccine efficacy and emerging variants.

Researchers identify deletions in the N-terminal domain of the spike protein that allow the coronavirus to avoid antibody neutralization and that may contribute to the emergence of new variants.

Facing new variants of SARS-CoV-2, some vaccines may offer more robust protection or be more easily redesigned to target them.

SARS-CoV-2 antibodies detected in blood donor samples indicate infections could have occurred in the US more than a month before the first confirmed case, but some experts remain skeptical.

Outcomes in COVID-19 patients may be better in those recently infected with endemic coronaviruses. 

Fewer than 1 in 10 dialysis patients sampled had antibodies against the novel coronavirus as of July, indicating that the greater population is far from levels required to achieve herd immunity.

Adenovirus vectors deliver the genetic instructions for SARS-CoV-2 antigens directly into patients’ cells, provoking a robust immune response. But will pre-existing immunity from common colds take them down?